Group Hopes to Turn Around Failed Lung Cancer Drugs

Drug Industry Daily
A UK coalition of drugmakers and a cancer research group are launching an analysis of failed Phase III lung cancer drug trials that will search for treatments that, despite failing overall, are effective for certain subpopulations.

To View This Article:


Subscribe To Drug Industry Daily